ADAPTIMMUNE THERAPEUTICS ($ADAP) posted quarterly earnings results on Tuesday, May 13th. The company reported earnings of -$0.18 per share, missing estimates of -$0.12 by $0.06. The company also reported revenue of $7,290,000, beating estimates of $6,297,775 by $992,225.
You can see Quiver Quantitative's $ADAP stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ADAPTIMMUNE THERAPEUTICS Insider Trading Activity
ADAPTIMMUNE THERAPEUTICS insiders have traded $ADAP stock on the open market 17 times in the past 6 months. Of those trades, 0 have been purchases and 17 have been sales.
Here’s a breakdown of recent trading of $ADAP stock by insiders over the last 6 months:
- ADRIAN RAWCLIFFE (Chief Executive Officer) has made 0 purchases and 4 sales selling 90,170 shares for an estimated $52,412.
- ELLIOT NORRY (Chief Medical Officer) has made 0 purchases and 4 sales selling 27,779 shares for an estimated $16,163.
- WILLIAM C JR BERTRAND (Chief Operating Officer) has made 0 purchases and 4 sales selling 25,126 shares for an estimated $14,603.
- JOHN LUNGER (Chief Patient Supply Officer) has made 0 purchases and 4 sales selling 25,126 shares for an estimated $14,603.
- CINTIA PICCINA (Chief Commercial Officer) sold 12,991 shares for an estimated $7,467
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ADAPTIMMUNE THERAPEUTICS Hedge Fund Activity
We have seen 22 institutional investors add shares of ADAPTIMMUNE THERAPEUTICS stock to their portfolio, and 39 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MATRIX CAPITAL MANAGEMENT COMPANY, LP removed 37,681,515 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $20,299,032
- TWO SEAS CAPITAL LP added 14,835,146 shares (+inf%) to their portfolio in Q4 2024, for an estimated $7,991,693
- BAILLIE GIFFORD & CO removed 11,819,095 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $2,328,361
- LONG FOCUS CAPITAL MANAGEMENT, LLC added 7,194,503 shares (+54.1%) to their portfolio in Q4 2024, for an estimated $3,875,678
- PFM HEALTH SCIENCES, LP removed 5,128,818 shares (-51.3%) from their portfolio in Q4 2024, for an estimated $2,762,894
- BANK OF AMERICA CORP /DE/ removed 1,790,995 shares (-38.5%) from their portfolio in Q4 2024, for an estimated $964,809
- RENAISSANCE TECHNOLOGIES LLC added 869,949 shares (+52.5%) to their portfolio in Q4 2024, for an estimated $468,641
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ADAPTIMMUNE THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $ADAP in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Scotiabank issued a "Outperform" rating on 03/21/2025
To track analyst ratings and price targets for ADAPTIMMUNE THERAPEUTICS, check out Quiver Quantitative's $ADAP forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
